Arbor's Bid For XenoPort Likely Driven By Effort To Grow Horizant
With minimal unencumbered pipeline assets to offer, XenoPort's value to Arbor apparently lies in positive sales trends for the modest-selling restless legs and postherpetic neuralgia drug.
You may also be interested in...
Dr Reddy's Laboratories will take XenoPort's clinical-stage oral psoriasis NCE, XP23829, further in the US, infusing new hope in the prodrug of monomethyl fumarate (MMF) that has seen some safety issues in earlier studies and faces significant competition in the space.
GlaxoSmithKline and XenoPort have decided to resolve their differences over Horizant (gabapentin enacarbil) extended-release tablets by terminating their collaboration. XenoPort now intends to hire a contract sales force in an attempt to do a better job on its own of commercialising the product.
The US FDA has approved XenoPort's and GlaxoSmithKline's application for Horizant (gabapentin enacarbil) extended release as a therapy for adults to manage postherpetic neuralgia (PHN), a chronic type of neuropathic pain that can follow the resolution of shingles.